Evaluation of Cellular Changes and Immunohistochemistry Expression of p53 and p16 in the Oral Mucosa Among Saudi Smokers.

Background: Smoking is a well-known risk factor for various health problems, including oral cancer. P16 and P53 proteins are involved in cell cycle regulation and proliferation, and their expression levels can provide insights into cellular health.

Objective: This study aims to evaluate the cellular changes and immunohistochemistry expression of p53 and p16 in the oral mucosa among Saudi smokers.

Ammonia scavenger and glutamine synthetase inhibitors cocktail in targeting mTOR/β-catenin and MMP-14 for nitrogen homeostasis and liver cancer.

The glutamine synthetase (GS) facilitates cancer cell growth by catalyzing de novo glutamine synthesis. This enzyme removes ammonia waste from the liver following the urea cycle. Since cancer development is associated with dysregulated urea cycles, there has been no investigation of GS's role in ammonia clearance.

Gestational diabetes among Saudi women: prevalence, risk factors and pregnancy outcomes.

Background And Objectives: The prevalence of gestational diabetes (GDM) has increased recently worldwide, mainly due to adoption of the International Association of Diabetes and Pregnancy Study Group (IADPSG) criteria. The objectives of this study were to determine the prevalence of GDM in Saudi women and to assess risk factors and pregnancy outcomes using the IADPSG criteria.

Design And Setting: A prospective descriptive study of pregnant Saudi women presenting at the Maternity and Children Hospital, Medina, Saudi Arabia, between October 2011 and June 2014.

Intestinal motility in acute uremia and effects of erythropoietin.

Objective: To investigate intestinal motility changes due to uremia, and the effect of pretreatment with erythropoietin.

Methods: This randomized control study was conducted in the Department of Physiology, Faculty of Medicine, Ain Shams University, Cairo, Egypt from September 2010 to July 2011. Forty adult female Wistar albino rats were allocated into 3 groups: control group, gentamicin-treated group, receiving intraperitoneal gentamicin sulphate (100 mg/kg for 5 days), and erythropoietin-gentamicin-treated group, receiving subcutaneous erythropoietin (1000 IU/kg for 3 days) prior to gentamicin injection.